BridgeBio Pharma, Inc. (MUN:2CL)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.88B +78.2% |
| Revenue (ttm) | 503.00M +355.2% |
| Net Income | -625.80M |
| EPS | -3.25 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 72.62 |
| Previous Close | n/a |
| Day's Range | 69.13 - 72.62 |
| 52-Week Range | 40.12 - 75.53 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About BridgeBio Pharma
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio files to sell 24.63M shares of common stock for holders
17:21 EDT BridgeBio (BBIO) files to sell 24.63M shares of common stock for holders
BridgeBio announces FDA acceptance of encaleret NDA
BridgeBio (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1. The…
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockb...
BridgeBio price target raised to $93 from $82 at Citi
Citi raised the firm’s price target on BridgeBio (BBIO) to $93 from $82 and keeps a Neutral rating on the shares. The firm adjusted models in the smid-cap biotech group…
BridgeBio price target raised to $120 from $110 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $120 from $110 and keeps a Buy rating on the shares. The firm says the company’s acoramidis may benefit…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (...
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% pr...
BridgeBio announces PROPEL 3 trial met primary endpoint
BridgeBio (BBIO) Pharma announced that positive results from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, were published as an original research arti...
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically sig...
BridgeBio Pharma Slides: Conference presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 28, 2026.
BridgeBio Pharma Transcript: AGM 2026
The meeting covered director elections, executive compensation, auditor ratification, and stock plan amendments, with all proposals approved by majority vote. No questions were raised by stockholders, and voting results will be filed with the SEC.
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio price target lowered to $96 from $106 at Mizuho
Mizuho lowered the firm’s price target on BridgeBio (BBIO) to $96 from $106 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1…
BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference 2026
The session highlighted robust growth for Attruby, driven by clinical differentiation and strong market uptake, with three late-stage products nearing launch. Pipeline programs target rare genetic diseases with significant pricing power and expansion opportunities, supported by ongoing life cycle management.
Canaccord starts BridgeBio on Attruby launch, pipeline
Canaccord initiated coverage of BridgeBio (BBIO) with a Buy rating and $104 price target The firm is “bullish as ever” on the transthyretin amyloid cardiomyopathy space. Canaccord cites BridgeBio’s co...
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
BridgeBio initiated with a Buy at Canaccord
Canaccord initiated coverage of BridgeBio (BBIO) with a Buy rating and $104 price target
BridgeBio price target raised to $98 from $94 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BridgeBio (BBIO) to $98 from $94 and keeps an Overweight rating on the shares after the company announced the FDA has accepted…
BridgeBio announces FDA acceptance, priority review of BBP-418 NDA
BridgeBio (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral BBP-418 for the treatment of individuals living with limb-girdle muscular…
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr...
BridgeBio downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Martin Auster downgraded BridgeBio (BBIO) to Market Perform from Outperform without a price target While Attruby continues to gain share, increasing “payer-driven risks” into the...
BridgeBio initiated with a Neutral at Citi
Citi analyst Eric Joseph initiated coverage of BridgeBio (BBIO) with a Neutral rating and $82 price target The firm sees the shares as range-bound in the medium term with the…